In patients after tibial distraction osteogenesis, teriparatide increased regenerate BMD more than no treatment after adjustment for phase differences.
In plain wordsIn patients after tibial bone transport, teriparatide increased new bone density more than no treatment.
- Peptide
- Teriparatide (PTH 1-34)
- Outcome
- IncreaseRegenerate bone mineral density increase
- Study
n = 16
- Comparator
- No treatment
- Outcome group
- Bone and joint · Musculoskeletal
- Studied dose
- 0.20 μg daily · subcutaneous · 8 weeksAs given in this study (human).
Measurements
- BMD increase
- 0.33 g/cm2
- teriparatide
- BMD increase
- 0.14 g/cm2
- no treatment
- Adjusted additional BMD increase
- 0.19 g/cm2
- teriparatide versus no treatment
- BMD increase ratio
- 2.43 ratio
- teriparatide versus no treatment
Source sentences
After adjustment for a potential phase difference, 8 weeks of Teriparatide treatment led to an additional 0.19 g/cm2 BMD increase (95%-CI:[0.11,0.28], p < 0.001).
4 context sentences(design, population, supporting numbers)
Overall BMD increased 0.14 g/cm2 in 8 weeks without treatment and 0.33 g/cm2 under Teriparatide treatment.
The ratio of the BMD increase between the two treatments was 0.33/0.14 = 2.43 (CI: [1.21,3.65]).
Sixteen patients with tibial defects after infection, underwent bone segment transport and at the time of docking the transport segment, were randomized to 8 weeks treatment with daily subcutaneous 0.20-μg Teriparatide injection followed by 8 weeks with no treatment,
The design was a cross-over study.